Jessie Gibson’s research focuses on characterization and treatment of non-motor symptoms of neurodegenerative diseases such as Huntington’s disease (HD) and Parkinson’s disease. She practiced as a nurse practitioner in behavioral and cognitive neurology at Vanderbilt University Medical Center, where she treated patients with neurodegenerative diseases including HD, PD, Lewy body dementia, progressive supranuclear palsy, multiple systems atrophy, Alzheimer’s disease, and corticobasal degeneration. She earned her PhD in nursing science from Vanderbilt University in 2019 and was co-PI on an investigator-sponsored study to test protocols for identification and treatment of neuropsychiatric symptoms in patients with HD. She joined the UVA School of Nursing in the summer of 2020 and has a secondary appointment in the Department of Neurology. Jessie is a member of the American Academy of Neurology and a credentialed investigator in the Huntington Study Group.
Gibson, J. S., & Springer, K. (2022). Social withdrawal in Huntington's disease: A scoping review. Journal of Huntington's Disease, 11(1), 17-24. https://doi.org/10.3233/JHD-210519
Considine, C. M., Hughes, S., Gibson, J. Sellers, Isaacs, D., McDonell, K., Darby, R. R., & Claassen, D. (2022). Anosognosia and memory encoding in Huntington disease. Cognitive and Behavioral Neurology, 35(1), 40-48. https://doi.org/10.1097/WNN.0000000000000293
Gibson, J. S., Rhoten, B. A., Ridner, S. H., & Claassen, D. O. (2022). Perceived effects of neuropsychiatric symptoms on functional status in early-stage Huntington disease. Western Journal of Nursing Research, 44(2), 141-150. https://doi.org/10.1177/0193945921992545
Gibson, J. S., Isaacs, D. A., Claassen, D. O., & Stovall, J. G. (2021). Lifetime neuropsychiatric symptoms in Huntington's disease: Implications for psychiatric nursing. Archives of psychiatric nursing, 35(3), 284-289. https://doi.org/10.1016/j.apnu.2021.03.006
Gibson, J. S., Ridner, S. H., Dietrich, M. S., Sohn, M. B., Rhoten, B. A., & Claassen, D. O. (2021). Measuring functional status in Huntington's disease. Movement Disorders, 36(3), 757-761. https://doi.org/10.1002/mds.28363
Rhoten, B. A., Sellers, J. I., Baraff, B., Holler, K. H., & Ridner, S. H. (2021). A qualitative examination of patient priorities and preferences during treatment decision-making for recurrent head and neck cancer. Support Care Cancer, 29(1), 377-385. https://doi.org/10.1007/s00520-020-05488-9 (2020)
Gibson, J. S., & Claassen, D. O. (2021). State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease. Expert Opinion on Pharmacotherapy, 22(8), 1015-1024. https://doi.org/10.1080/14656566.2021.1876666
Gibson, J. S., Hunter, C. B., & Hewitt, L. A. (2020). A call to action: The role of healthcare providers in reducing the burden associated with neurogenic orthostatic hypotension. Neurology and Therapy, 9, e205-11. https://doi.org/10.1007/s40120-020-00203-6
Isaacs, D., Gibson, J.S., Stovall, J. & Claassen, D.O. (2020). The impact of anosognosia on clinical and patient-reported assessments of psychiatric symptoms in Huntington’s disease. Journal of Huntington's Disease, 9(3), 291-302. https://doi.org/10.3233/JHD-200410
Sellers. J., Ridner, S. H., & Claassen, D. O. (2020). A systematic review of neuropsychiatric symptoms and functional capacity in Huntington's disease. Journal of neuropsychiatry and clinical neurosciences, 32(2), 109-124. https://doi.org/10.1176/appi.neuropsych.18120319.
Sellers, J., Darby, R. R., Farooque, A., & Claassen, D. O. (2019). Pimavanserin for psychosis in Parkinson's disease-related disorders: A retrospective chart review. Drugs & aging, 36(7), 647-653. https://doi.org/10.1007/s40266-019-00655-y.
Diehl, S. K., Mefferd, A. S., Lin, Y. C., Sellers, J., McDonell, K. E., de Riesthal, M., & Claassen, D. O. (2019). Motor speech patterns in Huntington disease. Neurology, 93(22), e2042-e2052. https://doi.org/10.1212/WNL.0000000000008541.